| Literature DB >> 30891549 |
Xiao-Yan Li1, Shuang-Shuang Lu1, Hong-Lun Wang2, Gang Li3, Yan-Feng He4, Xiao-Yu Liu1, Rong Rong1, Ji Li3, Xuan-Cheng Lu1.
Abstract
BACKGROUND: To study the antidiabetic effects and mechanisms of the fenugreek extracts in streptozotocin (STZ)-induced type 2 diabetic (T2DM) mice fed a high-fat diet (HFD).Entities:
Keywords: C57BL/6J mice; diabetes mellitus; fenugreek; hyperglycemia
Year: 2018 PMID: 30891549 PMCID: PMC6357430 DOI: 10.1002/ame2.12004
Source DB: PubMed Journal: Animal Model Exp Med ISSN: 2576-2095
Figure 1High‐performance liquid chromatography (HPLC) product chromatograms. A, Three standard substance (flavonoids), orientin (retention time [RT] = 10 min), vitexin (RT = 12 min), and isovitexin (RT = 14 min). B, Three standard substance (stilbene glycosides), rhaponticin (RT = 13 min), deoxyrhapontin (RT = 20 min), and leaves simple emodin (RT = 23 min). C, Fenugreek ethyl acetate extract. D, Fenugreek 30% n‐butyl alcohol extracts
Change in weight of type 2 diabetes mellitus (T2DM) mouse model
| Group/Week | Weight (g) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | |
| M Gr. | 21.00 ± 5.00 | 18.20 ± 3.70 | 19.00 ± 2.74 | 17.40 ± 2.97 |
| PC Gr. | 25.83 ± 2.83 | 24.00 ± 2.00 | 23.67 ± 2.25 | 22.83 ± 2.93 |
| E1H Gr. | 25.00 ± 5.10 | 22.00 ± 4.69 | 21.60 ± 3.51 | 21.40 ± 4.72 |
| E1L Gr. | 26.40 ± 4.51 | 22.20 ± 3.56 | 22.00 ± 3.81 | 22.20 ± 5.07 |
| E2H Gr. | 23.20 ± 3.63 | 21.00 ± 2.33 | 21.40 ± 2.07 | 20.60 ± 3.29 |
| E2L Gr. | 23.00 ± 3.16 | 21.8 ± 3.77 | 22.20 ± 3.42 | 20.40 ± 6.02 |
n = 10; M, T2DM model; PC, positive control; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.
Change in blood glucose level of type 2 diabetes mellitus (T2DM) mouse model
| Blood glucose level (mmol/L) | ||||
|---|---|---|---|---|
| Group/Week | Week 1 | Week 2 | Week 3 | Week 4 |
| M | 17.92 ± 0.97 | 17.12 ± 3.57 | 16.82 ± 3.67 | 17.68 ± 3.69 |
| PC | 15.00 ± 4.30 | 16.50 ± 4.95 | 10.00 ± 5.05 | 10.75 ± 4.35 |
| E1H | 16.50 ± 6.03 | 16.25 ± 5.38 | 13.67 ± 3.06 | 13.33 ± 6.43 |
| E1L | 16.20 ± 3.70 | 15.60 ± 4.83 | 16.00 ± 3.16 | 16.50 ± 7.93 |
| E2H | 17.33 ± 1.53 | 13.33 ± 4.04 | 13.33 ± 2.08 | 11.00 ± 1.60 |
| E2L | 17.00 ± 3.00 | 18.40 ± 1.95 | 16.00 ± 2.55 | 16.20 ± 5.76 |
n = 10; M, T2DM model; PC, positive control; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.
P < .01 compared with week 1 value of respective group.
P < .05 compared with week 1 value of respective group.
Change in serum antioxidant levels of type 2 diabetes mellitus (T2DM) mouse model
| Group/Index | SOD (IU/mL) | MDA (nM/mL) | CAT (IU/mL) |
|---|---|---|---|
| Normal | 98.43 ± 9.03 | 4.75 ± 0.35 | 68.42 ± 9.15 |
| M | 69.66 ± 3.93 | 12.57 ± 1.0 | 37.17 ± 7.21 |
| PC | 89.51 ± 2.06 | 7.41 ± 0.95 | 59.81 ± 9.60 |
| E1H | 88.86 ± 2.74 | 7.80 ± 1.16 | 51.67 ± 8.61 |
| E1L | 62.44 ± 8.47 | 9.83 ± 1.04 | 45.05 ± 8.60 |
| E2H | 87.08 ± 6.54 | 7.97 ± 1.24 | 52.25 ± 4.30 |
| E2L | 69.21 ± 1.38 | 7.74 ± 1.21 | 44.62 ± 6.28 |
P < .01, compared with normal group.
P < .01 compared with M group; n = 10; M, T2DM model; PC, positive control; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.
Fatty degeneration of liver and kidney
| Group | Blank | M | E1L | E1H | E2L | E2H | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Fatty degeneration in liver | N | N | +++ | +++ | N | N | + | N | N | + | N+ | N |
| Fatty degeneration in kidney | N | N | +++ | ++ | + | N | + | + | N | + | N | N |
N, no abnormity; +, slight lesioning; ++, no remarkable lesioning; +++, remarkable lesioning. M, T2DM model; E1H and E1L, flavonoid high and low doses, respectively; E2H and E2L, stilbene glycoside high and low doses, respectively.
Figure 2Histopathological changes in kidney, liver, and pancreas tissues stained with hematoxylin and eosin (H&E, ×200)